<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type='text/xsl' href='/oai/static/oai2.xsl' ?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-07-24T10:16:36Z</responseDate>
  <request identifier="a222ccef843060f8d83d748c631c1412396a3dd2bb3bd0bb2d1b0862d52ffce5" metadataPrefix="oai_ddi25" verb="GetRecord">https://datacatalogue.cessda.eu/oai-pmh/v0/oai</request>
  <GetRecord>
    <record>
    <header>
      <identifier>a222ccef843060f8d83d748c631c1412396a3dd2bb3bd0bb2d1b0862d52ffce5</identifier>
      <datestamp>2026-06-02T14:14:50Z</datestamp>
      <setSpec>language:sv</setSpec><setSpec>openaire_data</setSpec>
    </header>
      <metadata>
        <codeBook xmlns="ddi:codebook:2_5" version="2.5" xsi:schemaLocation="ddi:codebook:2_5 http://www.ddialliance.org/Specification/DDI-Codebook/2.5/XMLSchema/codebook.xsd">
    <docDscr>
      <citation>
        <titlStmt>
          <titl xml:lang="sv">Antioxidanter vid stapedotomi</titl>
        </titlStmt>
        <prodStmt>
          <producer xml:lang="en" abbr="SND">Swedish National Data Service</producer><producer xml:lang="sv" abbr="SND">Svensk nationell datatjänst</producer>
        </prodStmt>
        <holdings xml:lang="en" URI="https://doi.org/10.5878/002570">Landing page</holdings>
      </citation>
    </docDscr>
  <stdyDscr>
    <citation>
      <titlStmt>
        <titl xml:lang="sv">Antioxidanter vid stapedotomi</titl>
        <parTitl xml:lang="en">Antioxidants in stapedotomy</parTitl>
        <IDNo xml:lang="en" agency="SND">snd0974-1-1.0</IDNo><IDNo xml:lang="en" agency="DOI">https://doi.org/10.5878/002570</IDNo>
      </titlStmt>
      <rspStmt>
        <AuthEnty affiliation="Department of Clinical and Experimental Medicine, IKE, Linköping University" xml:lang="en">Fridberger, Anders
        </AuthEnty><AuthEnty affiliation="Institutionen för klinisk och experimentell medicin, IKE, Linköpings universitet" xml:lang="sv">Fridberger, Anders
        </AuthEnty>
      </rspStmt>
      <prodStmt>
        <prodDate xml:lang="en"/>
      </prodStmt>
      <distStmt>
        <distrbtr abbr="SND" URI="https://snd.gu.se" xml:lang="en">Swedish National Data Service</distrbtr><distrbtr abbr="SND" URI="https://snd.gu.se" xml:lang="sv">Svensk nationell datatjänst</distrbtr>
        <distDate xml:lang="en" date="2014-12-19">2014-12-19</distDate>
      </distStmt>
      <verStmt>
      </verStmt>
      <holdings xml:lang="en" URI="https://doi.org/10.5878/002570">Landing page</holdings>
    </citation>
    <stdyInfo>
      <subject>
        <keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D006309">Hearing</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D006309">Hörsel</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D034381">Hearing Loss</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D034381">Hörselnedsättning</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D004427">Ear Diseases</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D004427">Öronsjukdomar</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D000975">Antioxidants</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D000975">Antioxidanter</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D010040">Otosclerosis</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D010040">Otoskleros</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D006311">Hearing Disorders</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D006311">Hörselskador</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D010038">Otorhinolaryngologic Diseases</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D010038">Öron-näsa-halssjukdomar</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D012677">Sensation</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D012677">Förnimmelse</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D020011">Protective Agents</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D020011">Skyddsmedel</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D045504">Molecular Mechanisms of Pharmacological Action</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D045504">Molekylära mekanismer bakom farmakologisk verkan</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D009424">Nervous System Physiological Phenomena</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D009424">Nervsystemets fysiologi</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D011603">Psychophysiology</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D011603">Psykofysiologi</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D012678">Sensation Disorders</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D012678">Sensoriska störningar</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D020228">Pharmacologic Actions</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D020228">Farmakologisk verkan</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D020313">Specialty Uses of Chemicals</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D020313">Användning av kemikalier och läkemedel</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D045505">Physiological Effects of Drugs</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D045505">Fysiologiska effekter av läkemedel</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D055687">Musculoskeletal and Neural Physiological Phenomena</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D055687">Muskel-skelettfysiologi och neurofysiologi</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D001525">Behavioral Sciences</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D001525">Beteendevetenskap</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D009461">Neurologic Manifestations</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D009461">Neurologiska manifestationer</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D010827">Physiology</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D010827">Fysiologi</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D011579">Psychological Phenomena</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D011579">Psykologiska fenomen</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D020164">Chemical Actions and Uses</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D020164">Kemisk verkan och användingsområden</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D026441">Mind-Body Therapies</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D026441">Kropp-själ och avslappningstekniker</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D009422">Nervous System Diseases</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D009422">Nervsystemets sjukdomar</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D012816">Signs and Symptoms</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D012816">Tecken och symtom</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D000529">Complementary Therapies</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D000529">Alternativ- och komplementärmedicin</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D001690">Biological Science Disciplines</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D001690">Biovetenskaper</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D004191">Behavioral Disciplines and Activities</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D004191">Beteendevetenskapliga discipliner och aktiviteter</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D013812">Therapeutics</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D013812">Behandlingsmetoder</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D013568">Pathological Conditions, Signs and Symptoms</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D013568">Patologiska tillstånd, tecken och symtom</keyword><keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D010811">Natural Science Disciplines</keyword><keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D010811">Naturvetenskaper</keyword>
        <topcClas xml:lang="en" vocab="Standard för svensk indelning av forskningsämnen 2011">Medical and Health Sciences</topcClas><topcClas xml:lang="sv" vocab="Standard för svensk indelning av forskningsämnen 2011">Medicin och hälsovetenskap</topcClas><topcClas xml:lang="en" vocab="Standard för svensk indelning av forskningsämnen 2011">Neurosciences</topcClas><topcClas xml:lang="sv" vocab="Standard för svensk indelning av forskningsämnen 2011">Neurovetenskaper</topcClas><topcClas xml:lang="en" vocab="CESSDA Topic Classification" vocabURI="https://vocabularies.cessda.eu/vocabulary/TopicClassification?code=Health">HEALTH</topcClas><topcClas xml:lang="sv" vocab="CESSDA Topic Classification" vocabURI="https://vocabularies.cessda.eu/vocabulary/TopicClassification?code=Health">HÄLSA</topcClas><topcClas xml:lang="en" vocab="Standard för svensk indelning av forskningsämnen 2011">Basic Medicine</topcClas><topcClas xml:lang="sv" vocab="Standard för svensk indelning av forskningsämnen 2011">Medicinska och farmaceutiska grundvetenskaper</topcClas>
      </subject>
      <abstract xml:lang="en">Background: Otosclerosis is a disorder that impairs middle ear function, leading to conductive hearing loss. Surgical treatment results in large improvement of hearing at low sound frequencies, but high-frequency hearing often suffers. A likely reason for this is that inner ear sensory cells are damaged by surgical trauma and loud sounds generated during the operation. Animal studies have shown that antioxidants such as N-Acetylcysteine can protect the inner ear from noise, surgical trauma, and some ototoxic substances, but it is not known if this works in humans. This trial was performed to determine whether antioxidants improve surgical results at high frequencies.  Methods: We performed a randomized, double-blind and placebo-controlled parallel group clinical trial at three Swedish university clinics. Using block-stratified randomization, 156 adult patients undergoing stapedotomy were assigned to intravenous N-Acetylcysteine (150 mg/kg body weight) or matching placebo (1:1 ratio), starting one hour before surgery. The primary outcome was the hearing threshold at 6 and 8 kHz; secondary outcomes included the severity of tinnitus and vertigo.  Findings: One year after surgery, high-frequency hearing had improved 2.7 ± 3.8 dB in the placebo group (67 patients analysed) and 2.4 ± 3.7 dB in the treated group (72 patients; means ± 95% confidence interval, p=0.54; linear mixed model). Surgery improved tinnitus, but there was no significant intergroup difference. Post-operative balance disturbance was common but improved during the first year, without significant difference between groups. Four patients receiving N-Acetylcysteine experienced mild side effects such as nausea and vomiting.  Conclusions: N-Acetylcysteine has no effect on hearing thresholds, tinnitus, or balance disturbance after stapedotomy  Purpose:  Otosclerosis is a disease of the middle ear that causes gradually increasing hearing loss. The stapes is gradually fixed inside the oval window, which leads to hearing impairment. The conventional treatment is surgical (stapedotomy): The stapes is partially replaced by drilling on its footplate and connecting a prosthesis. This results in great improvement of low-frequency hearing, but at frequencies above 4000 Hz, there is less improvement and in some cases even decline of hearing after surgery (see e.g. Meyer, 1999). This is considered a consequence of trauma to the high-frequency parts of the inner ear during drilling on the stapes footplate. During drilling, patients report loud sounds, often described as ”the worst sound I ever heard”.  In animals, antioxidants such as N-Acetylcysteine can protect the inner ear against noise-induced hearing loss. We will examine whether antioxidants lead to improved high-frequency hearing after stapedotomy. Our hypothesis is that antioxidants protect the inner ear against the trauma caused by the operation.  The dataset contains 9 variables: "id" is a number with range 1 - 145, unique for each patient. "medicin" denotes the type of treatment given (possible values are "N-Acetylcysteine" or "Placebo"). "beta" denotes whether the steroid betametason was given before surgery. "gender" is "f" for female patients and "m" for males. "weight" is each patient's weight in kg. "age" is the age (in years, at the time of surgery). "freq" denotes the type of measurement performed. There are several possible values. "Tinnitus" means that "air1" and "air2" contains the difference in tinnitus scores before and after surgery. "tmv" denotes that air1 contains the average hearing threshold across the frequencies 0.5 - 3 kHz. "disk" means that "air1" contains the difference in discrimination scores before and after surgery "dizziness" means that "air1" contains the difference in dizziness scores before and after surgery. "hearq" means that "air1" contains the difference in hearing quality scores before and after surgery "surgery" means that "air1" contains the patient's assessment of the outcome of the operation (10 is the best, 0 is the worst) Numbers "250", "500", "1000", "2000", "3000","4000", "6000" and "8000" means that "air1" contains the difference in hearing thresholds before and after surgery at this particular stimulus frequency. "air1" contains measurements acquired 6 - 8 weeks after surgery. "air2" contains measurements acquired 1 year after surgery.</abstract><abstract xml:lang="sv">Bakgrund: Otoskleros är en sjukdom som försämrar mellanörats funktion, vilket leder till hörselnedsättning. Kirurgisk behandling förbättrar hörseln vid låga stimuleringsfrekvenser, men högfrekvenshörseln förbättras inte. En trolig anledning till de sämre resultaten vid höga frekvenser är att innerörats sinnesceller skadas av det kirurgiska traumat och ljud som alstras under operationen. Djurstudier har visat att antioxidanter, tex N-Acetylcystein, kan skydda innerörat mot bullerskador, kirurgiskt trauma, och vissa ototoxiska substanser, men det är inte känt om detta fungerar hos människa. Syftet med denna studie är att undersöka om antioxidanter förbättrar kirurgiska resultat vid höga frekvenser. Metoder: Vi har genomfört en randomiserad, dubbelblind och placebokontrollerad klinisk studie vid tre svenska universitetskliniker. Stratifierad randomisering användes för att slumpa 156 patienter till behandling med antingen intravenöst N-Acetylcystein (150 mg/kg kroppsvikt) eller matchande placebo (kvot 1:1), med start en timme innan operationen. Primärt utfallsmått var hörtröskeln vid 6 och 8 kHz, sekundära effektmått tinnitus och yrsel. Resultat: Ett år efter operationen hade högfrekvenshörseln förbättrats med 2.7 ± 3.8 dB i placebogruppen (67 patienter analyserade) och med 2.4 ± 3.7 dB i den behandlade gruppen (72 patienter; medelvärde ± 95% konfidensintervall, p=0.54, linjär mixad modell). Operationen förbättrade patienternas tinnitus, men utan signifikant skillnad mellan grupperna. Balansstörningar var vanligt förekommande, men förbättrades under det första året, utan att någon signifikant skillnad mellan grupperna förelåg. Milda biverkningar observerades hos fyra patienter i N-Acetylcysteingruppen (illamående och kräkningar). Slutsats: N-Acetylcystein påverkar inte hörtrösklar, tinnitus eller balansstörningar efter stapedotomi.  Syfte:  Otoskleros är en öronsjukdom som ger en långsamt tilltagande hörselnedsättning. Stigbygeln fixeras gradvis i ovala fönstret och dess rörelser hämmas, vilket leder till hörselnedsättning. Den gängse behandlingen är kirurgisk (stapedotomi): stigbygelns platta borras upp och man kopplar in en protes som delvis ersätter stigbygeln. Detta ger en stor förbättring av hörseln framförallt vid låga frekvenser, men vid frekvenser ovanför 4000 Hz ses en mindre förbättring och i en del fall tom en försämring efter operationen (se tex Meyer, 1999). Detta anses bero på det trauma som innerörats högfrekvensdelar utsätts för då stigbygelns platta borras upp. Under borrningen upplever patienten starka ljud, som ofta beskrivs som "det värsta jag någonsin hört".  Hos försöksdjur kan antioxidanter, tex acetylcystein, skydda innerörat mot bullerskador. Vi vill undersöka om tillförsel av antioxidanter kan ge förbättrad högfrekvenshörsel efter stapedotomi. Vår hypotes är att antioxidanterna skyddar innerörat mot det trauma som operationen innebär.  The dataset contains 9 variables: "id" is a number with range 1 - 145, unique for each patient. "medicin" denotes the type of treatment given (possible values are "N-Acetylcysteine" or "Placebo"). "beta" denotes whether the steroid betametason was given before surgery. "gender" is "f" for female patients and "m" for males. "weight" is each patient's weight in kg. "age" is the age (in years, at the time of surgery). "freq" denotes the type of measurement performed. There are several possible values. "Tinnitus" means that "air1" and "air2" contains the difference in tinnitus scores before and after surgery. "tmv" denotes that air1 contains the average hearing threshold across the frequencies 0.5 - 3 kHz. "disk" means that "air1" contains the difference in discrimination scores before and after surgery. "dizziness" means that "air1" contains the difference in dizziness scores before and after surgery. "hearq" means that "air1" contains the difference in hearing quality scores before and after surgery. "surgery" means that "air1" contains the patient's assessment of the outcome of the operation (10 is the best, 0 is the worst). Numbers "250", "500", "1000", "2000", "3000","4000", "6000" and "8000" means that "air1" contains the difference in hearing thresholds before and after surgery at this particular stimulus frequency. "air1" contains measurements acquired 6 - 8 weeks after surgery. "air2" contains measurements acquired 1 year after surgery.</abstract>
      <sumDscr>
        <collDate xml:lang="en" date="2007-12-01" event="start">2007-12-01</collDate><collDate xml:lang="en" date="2013-04-30" event="end">2013-04-30</collDate>
        <anlyUnit xml:lang="en">Individual<concept/></anlyUnit><anlyUnit xml:lang="sv">Individ<concept/></anlyUnit>
      </sumDscr>
    </stdyInfo>
    <method>
      <dataColl>
        <sampProc xml:lang="en">Probability: Stratified<concept/></sampProc><sampProc xml:lang="sv">Sannolikhetsurval: stratifierat urval<concept/></sampProc><sampProc xml:lang="en">Probability<concept/></sampProc><sampProc xml:lang="sv">Sannolikhetsurval<concept/></sampProc>
        <collMode xml:lang="en">Physical measurements and tests<concept/></collMode><collMode xml:lang="sv">Fysiska mätningar och tester<concept/></collMode>
      </dataColl>
    </method>
    <dataAccs>
      <useStmt>
        <restrctn xml:lang="en">Access to data through SND. Data are freely accessible.</restrctn><restrctn xml:lang="sv">Åtkomst till data via SND. Data är fritt tillgängliga.</restrctn>
      </useStmt>
    </dataAccs>
    <othrStdyMat>
    </othrStdyMat>
  </stdyDscr>
  <fileDscr>
  </fileDscr>
</codeBook>
      </metadata>
      <about>
        <provenance xmlns="http://www.openarchives.org/OAI/2.0/provenance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/provenance http://www.openarchives.org/OAI/2.0/provenance.xsd">
    <originDescription harvestDate="2026-06-02T14:14:50Z" altered="true">
      <baseURL>https://snd.gu.se</baseURL>
      <identifier>snd0974-1</identifier>
      <datestamp>2017-01-02T18:57:36Z</datestamp>
      <metadataNamespace>ddi:codebook:2_5</metadataNamespace>
    </originDescription>
</provenance>
      </about>
    </record>
  </GetRecord>
</OAI-PMH>